Barinthus price target lowered to $9.50 from $11 at Alliance Global Partners

Alliance Global Partners lowered the firm’s price target on Barinthus Biotherapeutics to $9.50 from $11 and keeps a Buy rating on the shares post the Q2 report. The company emphasied the ongoing development of its lead VTP-300 product candidate, a T-cell stimulating immunotherapeutic, in chronic hepatitis B virus, the analyst tells investors in a research note.